Skip to content
DataLookout
Menu

Solar-StageNCT06235151

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 17 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Primary completion date changed from estimate of Sep 2026 to Oct 30, 2026
    • Enrollment target: estimated 439 to confirmed 443
  2. Notable Eligibility criteria expanded, about 12 words Show 5 more changesShow less
    • Primary and study completion dates: Sep 2026 to Oct 2026
    • Interventions: Copper Cu 64 PSMA I&T (Drug) to Copper Cu 64 PSMA I&T (Drug)
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description revised
    • Site details revised at 3 of 43 sites
  3. Minor Enrollment closed, study ongoing
    • Study sites: 44 to 43
    v16
  4. Minor Study sites: 43 to 44
    • Secondary endpoints: 2 to 3
    v15
  5. Minor Primary and study completion pushed from Mar 2026 to Sep 2026
    • Site details revised at 1 of 43 sites
    v14
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Enrollment target: 323 to 439
    • Study description revised
    v13
  2. Minor Study sites: 41 to 43v12
  3. Minor Study sites: 40 to 41v11
  4. Notable Primary and study completion dates: Jul 2025 to Mar 2026
    • Study sites: 39 to 40
    v10
  5. Minor Study sites: 38 to 39v9
  6. Minor Study sites: 39 to 38v7
  7. Minor Study sites: 36 to 39v6
  8. Minor Study sites: 35 to 36v5
  9. Minor Study sites: 17 to 35v4
  10. Notable Eligibility criteria expanded, about 1 word
    • Study sites: 9 to 17
    v3
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 9
    • Start date changed from estimate of Feb 2024 to Apr 1, 2024
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Sensitivity
Timeframe: 4 Hours
Specificity
Timeframe: 4 Hours

Secondary (3)

Inter-reader and intra-reader agreement of copper Cu 64 PSMA I&T PET/CT interpretation on a per-patient basis
Incidence of adverse events in copper Cu 64 PSMA I&T injection
Positive Predictive Value and Negative Predictive Value

Arms and interventions

Diagnostic Imaging with Copper Cu 64 PSMA I&TExperimental

Copper Cu 64 PSMA I\&T Injection

Drugs: Copper Cu 64 PSMA I&T

Sites

43 sites in 1 country